Stay updated with breaking news from Daniel Vitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
<iframe src=https://www.youtube.com/embed/-1tdPdVJr_M></iframe>Dr Daniel Vitt, CEO of Immunic Inc , discusses the company's encouraging first-quarter performance with Proactive.The... | May 16, 2023
– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal...
Immunic shares are higher Thursday after the company announced its results for the first quarter ended March 31 and issued a corporate update. "In the first...
Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update Positive Results From Phase 1b Clinical... | May 11, 2023
Issuer: Immunic, Inc. / Key word(s): Study/Conference Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action 06.05.2023